Table 1.
Clinicopathological characteristics of AQP1 overexpression in 505 lung adenocarcinoma patients
| Variable | Total | AQP1 overexpression |
||
|---|---|---|---|---|
| Negative | Positive | p-value | ||
| Sex | .938 | |||
| Male | 247 | 196 (79.4) | 51 (20.6) | |
| Female | 258 | 204 (79.1) | 54 (20.9) | |
| Age (yr) | .092 | |||
| ≤ 60 | 181 | 136 (75.1) | 45 (24.9) | |
| > 60 | 324 | 264 (81.5) | 60 (18.5) | |
| Smoking history | .347 | |||
| Non-smoker | 302 | 235 (77.8) | 67 (22.2) | |
| Smoker | 203 | 165 (81.3) | 38 (18.7) | |
| Tumor size (cm) | .145 | |||
| ≤ 3 | 276 | 212 (76.8) | 64 (23.2) | |
| > 3 | 229 | 188 (82.1) | 41 (17.9) | |
| Histological grade | .097 | |||
| G1 | 34 | 30 (88.2) | 4 (11.8) | |
| G2 | 390 | 312 (80.0) | 78 (20.0) | |
| G3 | 81 | 58 (71.6) | 23 (28.4) | |
| Acinar predominant | .368 | |||
| No | 207 | 168 (81.2) | 39 (18.8) | |
| Yes | 298 | 232 (77.9) | 66 (22.1) | |
| Papillary predominant | .120 | |||
| No | 422 | 339 (78.0) | 93 (22.0) | |
| Yes | 83 | 71 (85.5) | 12 (14.5) | |
| Lepidic predominant | .087 | |||
| No | 472 | 370 (78.4) | 102 (21.6) | |
| Yes | 33 | 30 (90.9) | 3 (9.1) | |
| Solid predominant | .233 | |||
| No | 432 | 346 (80.1) | 86 (19.9) | |
| Yes | 73 | 54 (74.0) | 19 (26.0) | |
| Othersa | .552 | |||
| No | 487 | 387 (79.5) | 100 (20.5) | |
| Yes | 18 | 13 (72.2) | 5 (27.8) | |
| Pleural invasion | .131 | |||
| Absent | 283 | 231 (81.6) | 52 (18.4) | |
| Present | 222 | 169 (76.1) | 53 (23.9) | |
| Venous invasion | .035b | |||
| Absent | 377 | 307 (81.4) | 70 (18.6) | |
| Present | 130 | 93 (72.7) | 35 (27.3) | |
| Lymphatic invasion | .039b | |||
| Absent | 252 | 209 (82.9) | 43 (17.1) | |
| Present | 253 | 193 (75.5) | 62 (24.5) | |
| Perineural invasion | .290 | |||
| Absent | 469 | 369 (78.7) | 100 (21.2) | |
| Present | 36 | 31 (86.1) | 5 (13.9) | |
| pTNM stage | .072 | |||
| I–II | 367 | 298 (81.2) | 69 (18.8) | |
| III–IV | 138 | 102 (73.9) | 36 (26.1) | |
| Recurrence | .029b | |||
| No | 311 | 256 (82.3) | 55 (17.7) | |
| Yes | 194 | 144 (74.2) | 50 (25.8) | |
| Death | .130 | |||
| No | 415 | 334 (80.5) | 81 (19.5) | |
| Yes | 90 | 66 (73.3) | 24 (26.7) | |
| EGFR mutation (n = 484) | .583 | |||
| Wild type | 247 | 193 (78.1) | 54 (21.9) | |
| Mutant type | 237 | 190 (80.2) | 47 (19.8) | |
| KRAS mutation (n = 413) | .326 | |||
| Wild type | 388 | 311 (80.2) | 77 (19.8) | |
| Mutant type | 25 | 18 (72.0) | 7 (28.0) | |
| ALK translocation (n = 440) | .089 | |||
| Wild type | 412 | 334 (81.1) | 79 (18.9) | |
| Mutant type | 28 | 19 (67.9) | 9 (32.1) | |
Values are presented as number (%).
AQP1, aquaporin 1; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.
a
Invasive mucinous and micropapillary subtype;
b
Statistically significant value.